Dr Ryan O’Hare Doig, Head, Spinal Cord injury Research (SAHMRI)
Neil Sachse Centre for Spinal Cord Research (SAHMRI)
SOUTH AUSTRALIA
AUSTRALIA
Dr. Ryan O’Hare Doig’s early research career has focused on understanding the pathophysiology of secondary degeneration following neurotrauma to the central nervous system (CNS). He uses innovative analytical techniques to demonstrate biochemical, molecular and gross anatomical changes that occur following CNS injury. Dr. O’Hare Doig has developed and optimised a combinatorial treatment strategy incorporating pharmacotherapeutics for the treatment of CNS injury. Ryan’s combinatorial strategy has been assessed in a clinically relevant model of spinal cord injury (SCI), demonstrating significant functional recovery and tissue sparing, crucial for the translation of his research into clinical trials.
In 2017, Ryan joined the South Australian Health & Medical Research Institute (SAHMRI) and the Neil Sachse Centre for Spinal Cord Research, to provide his expertise in SCI and other neurotrauma models. Dr. O’Hare Doig’s lab looks to help develop new techniques to provide a more accurate diagnosis and prognosis of SCI, and to identify potential treatment strategies in a clinical setting.
-
Liver cancer & patient-derived tumour organoids
Dr Benjamin Dwyer is a translational cancer researcher driven by a clear purpose: to ensure discoveries made in the laboratory genuinely improve outcomes for patients.
Based at Curtin University, he established and now leads the organoid platform within the Liver Cancer Collaborative and directs the WA Organoid Innovation Hub, working at the intersection of biology, medicine and biotechnology to accelerate new treatments for liver cancer.
-
Targeting chemotherapy resistance in ovarian cancer patients
Dr Alex Cole, from the Centenary Institute’s Centre for Biomedical AI, is now leading the research focused on developing a new treatment to counteract a protein called follistatin (FST), known for making ovarian cancer cells resistant to chemotherapy.
By employing cutting-edge molecular biology and directed evolution techniques, the project aims to create nanobodies—small, precise molecules—that can block FST. If successful, these nanobodies could enhance the effectiveness of chemotherapy and improve ovarian cancer treatment rates.
-
Identification & characterisation of molecular drivers of therapeutic resistance
Professor Pieter Eichhorn is an internationally experienced cancer biologist and research leader whose career has been defined by high-impact contributions at the interface of functional genomics, translational oncology, and research infrastructure strategy.
He completed his PhD at the University of Newcastle upon Tyne, contributing to the cloning of the gene associated with Cornelia de Lange Syndrome, before undertaking postdoctoral training at the Netherlands Cancer Institute in the laboratory of René Bernards. There, he performed pioneering functional genetic screens that identified key regulators of oncogenesis and therapy resistance, including critical roles for the PI3K signalling pathway in resistance to targeted breast cancer therapies.
